BRPI0511481A - uso - Google Patents
usoInfo
- Publication number
- BRPI0511481A BRPI0511481A BRPI0511481-0A BRPI0511481A BRPI0511481A BR PI0511481 A BRPI0511481 A BR PI0511481A BR PI0511481 A BRPI0511481 A BR PI0511481A BR PI0511481 A BRPI0511481 A BR PI0511481A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- ruminants
- isomer
- energy balance
- negative
- Prior art date
Links
- 241000282849 Ruminantia Species 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000007976 Ketosis Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000004140 ketosis Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000003142 Retained Placenta Diseases 0.000 abstract 1
- 206010038758 Retained placenta or membranes Diseases 0.000 abstract 1
- 206010046793 Uterine inflammation Diseases 0.000 abstract 1
- 210000003165 abomasum Anatomy 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 208000010515 dystocia Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 208000030175 lameness Diseases 0.000 abstract 1
- 208000004396 mastitis Diseases 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 231100000621 toxification Toxicity 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de um composto de fórmula (I) um isómero do mesmo, um pró-fármaco do composto ou do referido isómero, ou um sal farmaceuticamente aceitável do composto, do isómero ou do pró-fármaco dito, na manufatura de um medicamento para o tratamento paliativo, profilático ou curativo do balanço de energia negativo em ruminantes. Uso de um composto de fórmula (I), na manufatura de um medicamento para o tratamento paliativo, profilático ou curativo da doença do ruminante associado com o balanço de energia negativo em ruminantes, onde, preferivelmente, a doença do ruminante associada ao balanço de energia negativo em ruminantes seja selecionado de síndrome do fígado gorduroso, distocia, disfunção imunológica, função imunológica diminuída, toxificação, cetose primária, cetose secundário, doença da vaca caída, indigestão, inapetência, placenta retida, abomaso deslocado, mastite, (endo-)-metrite, infertilidade, baixa fertilidade, e claudicação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57417104P | 2004-05-25 | 2004-05-25 | |
| PCT/IB2005/001438 WO2005115389A2 (en) | 2004-05-25 | 2005-05-13 | Specific ppar agonists for treating negative energy balance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511481A true BRPI0511481A (pt) | 2007-12-26 |
Family
ID=34967765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511481-0A BRPI0511481A (pt) | 2004-05-25 | 2005-05-13 | uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070281935A1 (pt) |
| EP (1) | EP1753426A2 (pt) |
| JP (1) | JP2008500323A (pt) |
| CN (1) | CN1956719A (pt) |
| AR (1) | AR049185A1 (pt) |
| AU (1) | AU2005247164B2 (pt) |
| BR (1) | BRPI0511481A (pt) |
| CA (1) | CA2567398A1 (pt) |
| IL (1) | IL179244A0 (pt) |
| MX (1) | MXPA06013754A (pt) |
| NO (1) | NO20065038L (pt) |
| RU (1) | RU2353362C2 (pt) |
| TW (1) | TWI280879B (pt) |
| WO (1) | WO2005115389A2 (pt) |
| ZA (1) | ZA200609235B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568009A1 (en) * | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Use of ppar agonists to treat ruminants |
| GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| ES2357992T3 (es) * | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
| GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| EP2137150A1 (en) * | 2007-03-12 | 2009-12-30 | Biolipox AB | Piperidinones useful in the treatment of inflammation |
| ES2590482T3 (es) * | 2008-12-02 | 2016-11-22 | Dupont Nutrition Biosciences Aps | Cepas y métodos para mejorar la salud y/o el rendimiento de los rumiantes |
| DE102009038123A1 (de) | 2009-08-17 | 2011-02-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| CN116162056A (zh) * | 2021-11-24 | 2023-05-26 | 上海医药工业研究院 | β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用 |
| WO2024145931A1 (zh) * | 2023-01-06 | 2024-07-11 | 上海医药工业研究院有限公司 | β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2340734A1 (fr) * | 1976-02-13 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de la m-trifluoromethylphenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments |
| AU683121B2 (en) * | 1993-12-23 | 1997-10-30 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| PT1567493E (pt) * | 2002-11-26 | 2009-04-09 | Pfizer Prod Inc | Activadores de ppar |
| EP1622569B1 (en) * | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| CA2568009A1 (en) * | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Use of ppar agonists to treat ruminants |
-
2005
- 2005-05-13 US US11/569,513 patent/US20070281935A1/en not_active Abandoned
- 2005-05-13 MX MXPA06013754A patent/MXPA06013754A/es unknown
- 2005-05-13 CA CA002567398A patent/CA2567398A1/en not_active Abandoned
- 2005-05-13 JP JP2007514167A patent/JP2008500323A/ja active Pending
- 2005-05-13 EP EP05738586A patent/EP1753426A2/en not_active Withdrawn
- 2005-05-13 AU AU2005247164A patent/AU2005247164B2/en not_active Ceased
- 2005-05-13 BR BRPI0511481-0A patent/BRPI0511481A/pt not_active IP Right Cessation
- 2005-05-13 RU RU2006141628/15A patent/RU2353362C2/ru not_active IP Right Cessation
- 2005-05-13 CN CNA2005800167704A patent/CN1956719A/zh active Pending
- 2005-05-13 WO PCT/IB2005/001438 patent/WO2005115389A2/en not_active Ceased
- 2005-05-20 TW TW094116567A patent/TWI280879B/zh not_active IP Right Cessation
- 2005-05-23 AR ARP050102112A patent/AR049185A1/es not_active Application Discontinuation
-
2006
- 2006-11-02 NO NO20065038A patent/NO20065038L/no not_active Application Discontinuation
- 2006-11-06 ZA ZA200609235A patent/ZA200609235B/xx unknown
- 2006-11-13 IL IL179244A patent/IL179244A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR049185A1 (es) | 2006-07-05 |
| CN1956719A (zh) | 2007-05-02 |
| NO20065038L (no) | 2006-12-01 |
| RU2006141628A (ru) | 2008-05-27 |
| IL179244A0 (en) | 2007-03-08 |
| TWI280879B (en) | 2007-05-11 |
| RU2353362C2 (ru) | 2009-04-27 |
| TW200607501A (en) | 2006-03-01 |
| WO2005115389A3 (en) | 2006-11-16 |
| AU2005247164B2 (en) | 2008-11-27 |
| ZA200609235B (en) | 2008-08-27 |
| CA2567398A1 (en) | 2005-12-08 |
| AU2005247164A1 (en) | 2005-12-08 |
| JP2008500323A (ja) | 2008-01-10 |
| WO2005115389A2 (en) | 2005-12-08 |
| US20070281935A1 (en) | 2007-12-06 |
| EP1753426A2 (en) | 2007-02-21 |
| MXPA06013754A (es) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511481A (pt) | uso | |
| Rodrigues | A review on the effects of mycotoxins in dairy ruminants | |
| Schweer et al. | The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs I: growth performance and digestibility | |
| Lai et al. | Responses to dietary levels of methionine in broilers medicated or vaccinated against coccidia under Eimeria tenella-challenged condition | |
| ES2196556T3 (es) | Formulacion en granulos para el tratamiento del tracto intestinal. | |
| AR027153A1 (es) | Sistema multitableta de oxibutinina para el tratamiento de la incontinencia | |
| PA8546101A1 (es) | Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas | |
| Kim et al. | Acetylsalicylic acid supplementation improves protein utilization efficiency while vitamin E supplementation reduces markers of the inflammatory response in weaned pigs challenged with enterotoxigenic E. coli | |
| Ahuja et al. | Pregnancy rate following GnRH+ PGF2α treatment of low body condition, anestrous Bos taurus by Bos indicus crossbred cows during the summer months in a tropical environment | |
| Birrell et al. | Vaccination against GnRH as a prelude to surgical castration of horses | |
| MXPA05007475A (es) | Alimento para animal con una fibra soluble y un alcohol de azucar y metodo de elaboracion y metodo de alimentacion. | |
| Orgeur et al. | The influence of rearing conditions on the social relationships of young male goats (Capra hircus) | |
| BRPI0511613A (pt) | uso de agonista de ppar | |
| TW200631579A (en) | Drugs and prodrugs useful for the treatment of energy balance in ruminants | |
| Sousa et al. | Establishment of an anesthetic protocol for semen collection by electroejaculation in six-banded armadillos (Euphractus sexcinctus Linnaeus, 1758) | |
| Guo et al. | Two melatonin treatments improve the conception rate after fixed‐time artificial insemination in beef heifers following synchronisation of oestrous cycles using the CoSynch‐56 protocol | |
| Gupta et al. | Ergot and fescue toxicoses | |
| Hendel et al. | PSII-22 trends in mycotoxin contamination in United States Corn | |
| Loescher et al. | Pharmacokinetics of non-steroidal anti-inflammatory drugs in male rabbits after acute and chronic administration and effect of chronic treatment on seminal prostaglandins, sperm quality and fertility | |
| BR0113294A (pt) | Aplicação de triazintrion-sulfóxidos para comebater coccidioses | |
| Torres-Lemus et al. | Influencia del aporte exógeno de progesterona (CIDR) post-inseminación artificial en ovejas primalas | |
| Privett et al. | PS3-6. The Effect of a Cheese Co-product in Swine Lactation Diets on Sow and Litter Performance | |
| Ashar et al. | Bumblefoot in a pigeon (Columba livia): A clinical | |
| Duygu et al. | Effect of Deslorelin on the Genital Tract in the Bitch: Mechanism of Action and Contraceptive Efficacy | |
| Kramarenko et al. | Analysis of long-term dynamics of reproductive characteristics of sows of the large white breed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/451 (2006.01), A61K 31/454 (2006.01), A61P |